Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001127602-20-009028)

Filing Details

Accession Number:: 0001127602-20-009028
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-03 16:35:50
Reporting Period:: 2020-02-28

Accepted Time:: 2020-03-03 16:35:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1682852	Moderna Inc.	MRNA	Biological Products, (No Disgnostic Substances) (2836)	813467528

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1690927	Zvi Tal Zaks	C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-02-28	10,000	$23.38	84,770	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2020-02-28	161,120	$0.00	161,120	$25.93
Common Stock	Restricted Stock Units	Acquisiton	2020-02-28	28,924	$0.00	28,924	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
161,120	2021-02-28	2030-02-28	No	4	A	Direct
28,924	2022-02-28		No	4	A	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan.
25% of this option will vest and become exercisable on February 28, 2021 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
50% of the shares subject to this restricted stock unit award will vest on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter.